Prior to joining Histogenics, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior Vice President of Technical Operations. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publicly-traded company that was acquired by Merz in 2010. His responsibilities included all business development, investor relations, strategic planning, and R&D functions, and he was part of the leadership team who led the Company’s IPO and subsequent acquisition by Merz. Mr. Gridley has held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. D and translational initiatives in the life sciences sector, and was recently appointed Managing Director.
The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.